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 Mycobacterium tuberculosis (Mtb) is the pathogen that causes Tuberculosis (TB) and is 
responsible for an average of 1.5 million deaths annually. Although a treatment regimen does exist, 
Multi-Drug Resistant (MDR-TB) and eXtremely Drug Resistant (XDR-TB) TB strains are becoming 
a more prevalent concern partly due to failure of patient compliance with the current six to nine 
month drug treatment regimen. The current diagnostic methods are not able to identify these MDR 
and XDR-TB strains efficiently therefore more effective point-of-care (POC) diagnostics and drug 
susceptibility testing (DST) are urgently needed to detect drug resistance and facilitate prompt, 
appropriate treatment plans. In order to detect TB and efficiently identify drug resistance, this 
project seeks to develop a novel diagnostic technology based on deoxyribozyme (DNAzyme) 
sensors. 
The overall goal of this project is to create an assay which combines Polymerase Chain 
Reaction (PCR) and DNAzymes to identify drug resistance conferring Single Nucleotide 
Polymorphisms (SNPs). To safely test the ability of DNAzyme sensors to detect SNPs indicative of 
multi-drug resistant TB, we have constructed a panel of drug resistant (drugR) nonpathogenic M. 
bovis BCG. We have designed a multiplex PCR that amplifies 6 chromosomal regions of the genome 
necessary for the species specific detection of TB and determination of a drug susceptibility profile 
based on the presence of SNPs. To improve the sensitivity and selectivity of the detection and DST 
of Mtb, we have designed and optimized DNAzyme sensor assays combined with multiplex PCR 
analytes that will enable the rapid, POC detection of drug resistance. This work aims to develop 
novel tools for the prompt and specific diagnosis of TB allowing for the implementation of an 
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effective treatment regimen that will ultimately lessen transmission and control the emerging global 
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  Mycobacterium tuberculosis (Mtb) is the pathogen that causes Tuberculosis (TB). One-third of 
the world’s population is currently infected with TB and it causes an average of 1.5 million deaths 
annually [1]. TB is spread through aerosolized droplets expelled from the lungs of an infected 
individual through talking, coughing, or sneezing wherein it may travel to the lungs of a new host 
and reside in pulmonary tissue [2]. Upon infection with Mtb, a patient can develop either the active 
or latent form of the disease. Active TB occurs when the body fails to control Mtb within alveolar 
macrophages and can result in pulmonary damage and dissemination to other areas of the body, 
both of which may ultimately result in death [3]. Individuals with active TB are infectious, will 
present with symptoms, and may test positive in a sputum smear microscopy test. Symptoms include 
a chronic cough, chest pain, fatigue, and weight loss [4]. Approximately 2 million people (or 90% of 
patients infected with Mtb) are latently infected with Mtb [5]. Latent TB infections result when the 
body effectively contains, but does not clear the infection. The patient will not present with 
symptoms because the bacilli become dormant within granulomas and the disease cannot be spread 
to others [6, 7]. The development of the granuloma, an immune structure formed to contain the 
infection, results in difficulties treating the infection [2]. Many of the currently used drugs are unable 
to effectively penetrate this barrier and bacilli in the granuloma are typically characterized by a 
phenotypically nonreplicative, dormant state [6, 7].  
Treatment of drug-susceptible TB consists of a four drug cocktail taken over a six to nine 
month period, however, due to the lengthy treatment regimen many patients fail to comply [8]. The 
current first-line drugs are isoniazid and rifampicin and when those become ineffective second-line 
drugs such as fluoroquinolones are used [5]. While a treatment regimen does exist, Multi-Drug 
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Resistant (MDR-TB) and eXtremely Drug Resistant (XDR-TB) TB strains are becoming increasingly 
prevalent due to failure to complete the drug regimen as well as the development of antibiotic 
tolerance. In 2012, approximately 450,000 people were diagnosed with MDR-TB and there were 
approximately 170,000 deaths due to MDR-TB that year [1]. Of those people with MDR-TB, 9% of 
the cases were XDR-TB [4]. Treatment for drug resistant tuberculosis is even more expensive, 
difficult to administer, accompanied by dangerous side effects, and requires a prolonged treatment 
of 18 to 24 months [5]. Due to these factors, noncompliance with treatment and mortality rates are 
even higher among these patients than those with drug-susceptible TB [1]. Single nucleotide 
polymorphisms (SNPs) in the drug targets of the TB genome are the major cause underlying the 
development of drug resistance [9]. Other mechanisms that may confer resistance occur through 
mutations that disrupt pro-drug activation or lead to u p-regulation of the target gene [5]. 
Currently we rely on suboptimal diagnostic technologies for the detection of Mtb which 
include sputum smear microscopy, culture based testing, and molecular diagnostics such as line-
probe assays and RT-PCR techniques like the GeneXpert. Sputum smear microscopy is the most 
common diagnostic test for TB [10]. It is ineffective due to the fact that it detects less than fifty 
percent of TB cases and even less in children and patients with HIV [10]. Also sputum smear 
microscopy is unable to differentiate between different mycobacterium species, such as Mycobacterium 
absessus (M.abs), for example, which requires its own multi-drug treatment regimen [11]. Culture-
based testing is extremely slow and presents a risk of infection to those conducting the protocol 
[10]. Molecular diagnostics, including line-probe assays and RT-PCR techniques like the GeneXpert, 
are the optimum methods for the detection of drug resistance, however they are not feasible due to 
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the high cost, technical expertise, and requirement of expensive instruments and cold storage of 
reagents which are typically not available in high burden areas [12]. 
Due to the limitations listed above, more efficient POC diagnostics and drug susceptibility 
testing (DST) are urgently needed to detect drug resistance and facilitate prompt, appropriate 
treatment plans. This project seeks to develop a novel diagnostic technology based on 
deoxyribozyme (DNAzyme) sensors for detection of TB and the identification of drug resistance. 
The overall goal is to create a POC assay which combines Polymerase Chain Reaction (PCR) and 





To understand the need to create a new diagnostic assay for the detection of TB and 
identification of drugR, a deeper knowledge of the pathology of the disease, the rising global threat 
of drug resistance, and current diagnostic technology available will be necessary. The discussion of 
methods that will be utilized for the development a novel diagnostic tool that can identify TB and its 
drug susceptibility, will follow. 
The Bacterium 
The evolution of Mycobacterium tuberculosis dates back thousands of years ago, beginning from 
tubercle bacilli in East Africa. This suggests that the pathogenic bacterium has affected the human 
race from the beginning of time, coevolving with its host to survive [13]. Members of the Mtb 
complex include Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium canettii, Mycobacterium 
microti, and Mycobacterium bovis [13]. While they differ widely in their preferred environment, 
phenotype, and pathogenicity, all cause pulmonary TB-like disease in mammals [14]. The bacteria of 
the Mtb complex are 99.9% similar at the DNA level and share identical hypervariable regions on 
their 16S and 23s rRNA sequences [15, 16]. Before the entire genome was sequenced, it was 
proposed that M. tuberculosis went through a steep reduction in the size of its genetic variation, 
otherwise known as a bottleneck, due to environmental events that date back to about 15-20,000 
years ago and was thought to have evolved to the human host from Mycobacterium bovis (M. bovis), the 
agent of bovine tuberculosis due to the high conservation within the species, however this is still up 
for debate [17-19]. The similarity between M. tuberculosis and M. bovis has enabled the development of 
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an M. bovis bacilli Calmette-Guerin (BCG) vaccine for the disease that is administered in countries 
with a high burden of TB [20, 21].  
M. tuberculosis is a member of the Actinomycete family and can be characterized by its 
unusually thick mycolic acid-rich cell well that allows it be acid-fast stained [22]. Mtb is a slow-
growing, intracellular pathogen, whose generation time of about 15-20 hours is thought to 
contribute to its virulence [22]. Mtb are exclusively mammalian pathogens, needing no 
environmental reservoir [22]. The bacterial adaptations of Mtb which allow for its survival in host 
immune cells have enabled it to become one of the most successful human pathogens and the 
mycobacteria continues to remain a major cause of death worldwide [23]. 
Pathology of Tuberculosis  
M. tuberculosis was the cause of White Plague of Europe in the 17th century and is still the 
leading cause of death due to a bacterial infectious disease worldwide [22]. The bacterium is spread 
through aerosolized, hydrophobic droplets expelled from a patient with the active disease that may 
be inhaled by another host [24]. Upon reaching the alveoli, the pathogen is taken up by alveolar 
macrophages and resides within the lung [24]. The macrophages, while unable to kill the 
mycobacteria, are able to produce an immune response that summons more macrophages and other 
immune cells to aggregate and form a granuloma, the hallmark lesion of TB [2]. The immune cells of 
the granuloma form a barrier around the bacteria in an effort to prevent the spread of the pathogen 
[25]. Studies have shown that the virulent mycobacteria are able to replicate within the macrophage 
and eventually cause macrophage cell death by inducing TNF suppression [26]. The pathogen is able 
to survive within dead and dying macrophage at the necrotic center of the granuloma [2].  
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Mtb’s ability to survive and replicate in macrophages is key to its survival with the host [2]. 
Once internalized by the macrophage, the pathogen resides within a phagosome [2]. The 
phagosomes role is to eradicate the pathogen through mechanisms such as acidification within a 
lysosome, reactive oxygen and nitrogen intermediates (ROS, RNI), proteolytic activity, and 
antimicrobial peptides [27]. Mtb is able to inhibit these phagosomal processes to avoid its death and 
create a favorable environment for replication. Their ability to avoid acidification is due to 
glycolipids known as sulfatides that prevent phagosome-lysosome fusion [28]. The cell wall of the 
pathogen consists mostly of lipids, specifically mycolic acids, which form a highly impermeable shell 
that prevents the deadly attack of cationic proteins, lysozyme, and oxygen radicals in the phagosome 
[22]. The pathogen also manipulates the phagosome to gain access to nutrients and creates an 
advantageous atmosphere for replication [27]. Mtb replicates very slowly within macrophages, which 
contributes to its virulence because the immune system may not recognize the bacteria right away 
[22]. The mycobacterium has also been known to infect other cell types, such as dendritic cells, 
neutrophils, and adipocytes as well [29]. The high burden of the increasing number of unrestricted, 
replicating mycobacteria cause the macrophage to undergo apoptosis, spreading the bacteria to new 
macrophages [2]. Once the initial macrophages burst, Mtb may be taken up by other migrating cells, 
such as lymphocytes and dendritic cells, which have been shown to facilitate its dissemination to 
distal tissues, like the spleen, liver, and central nervous system [22]. At this stage, the lymphocytes 
that come in contact with the pathogen are able to activate the immune system in an effort to 
destroy the life-threatening bug [22]. 
If the host’s immune system is not able to control the pathogen, the TB infection progresses 
to an active disease. Active TB occurs in 10% of infected patients due to immune suppressing 
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circumstances like HIV-coinfection, the use of immunosuppressive drugs, re-infection, or old age, 
which allows the bacilli to grow and multiply inside the host [30, 31]. Individuals with active TB are 
infectious, will present with symptoms, and may test positive in a sputum smear microscopy test [6]. 
Symptoms include a chronic cough, chest pain, production of sputum, weight loss, and fever, and 
may be fatal if not treated properly [32]. 
However, not everyone who breathes in the aerosolized pathogen develops the active form 
of the disease. About 90% of infected individuals are able to contain the bacteria within the 
granuloma in a noninfectious form known as latent tuberculosis, which is asymptomatic, sputum-
smear negative, and does not pose a health threat until the immune system becomes compromised 
and the TB can be reactivated [6]. The chance of reactivation creates an enormous reservoir of 
infection and makes the goal of eradicating this disease seem almost unattainable.  
The Challenge of Drug Resistance 
Each year, approximately 8 million people become infected with TB and over 95% of deaths 
due to the pathogen occur in low and middle income countries [33, 34]. Treatment regimens for 
active tuberculosis consists of combination of four drugs taken daily for 6-9 months [35]. The failure 
of patients to adhere to this lengthy treatment, as well as irregular drug supply and improper 
prescriptions, make the global eradication of TB difficult and contribute to its drug resistance [36].  
M. tuberculosis has evolved many intrinsic and molecular mechanisms that also make it 
difficult to treat. It is difficult for antibiotics to penetrate the bacterium due to the impermeability of 
its mostly lipid cell envelop, therefore extended treatment is needed to be effective [37]. In its latent 
form, the non-replicating state of tuberculosis within the granuloma allows it to be tolerant to 
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antibiotics whose main mechanism of action is to attack the replication process of the mycobacteria 
[28]. The induction of efflux pumps within the macrophage can facilitate the survival of active TB 
within the granuloma, allowing antibiotic resistance to develop. [38, 39]. The localization of Mtb 
within host cells in various tissue sites contributes to the poor efficacy of therapeutics. The wall of 
the granuloma and poor vascularization also make it difficult for adequate levels of antibiotics 
penetrate to reach the tuberculosis, enabling the pathogen to slowly develop a resistance to the sub-
therapeutic treatment [27].  
On the molecular level, positive selection of spontaneous mutants harboring single 
nucleotide polymorphisms (SNPs) are the major contributor of drug resistance [9]. In recent years, 
the prevalence of drug resistant strains has been increasing, especially in China, India, and South 
Africa [23]. Multidrug-resistant tuberculosis (MDR-TB) is resistant to the first-line drugs, isoniazid 
(INH) and rifampin (RIF) and is caused by the inappropriate or incorrect use of antibiotics as 
described above. MDR-TB can be treated with second-line drugs such as fluoroquinolones, 
kanamycin, and capreomycin [35, 40]. However, second-line treatment, when available, is more 
costly and time extensive leading to even greater lack of compliance. The selective pressure created 
by the failure to complete the second-line treatment leads to eXtremly drug-resistant TB (XDR-TB) 
which is resistant to both first-line drugs, as well as at least one fluoroquinolone (FQ) and one 
second-line, injectable drug [41]. In 2013 alone, 480,000 people developed MDR-TB and 9% of 
these cases were estimated to be XDR-TB [36]. 
Mechanism of Drug Resistance 
The severity of the rising drug resistance epidemic is due, in part, to the many mechanisms 
that Mtb can use to gain resistance. As mentioned above, mechanisms of drug resistance include 
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intrinsic factors such as phenotypic drug tolerance mediated by efflux pumps, characteristic of its 
cell wall, and SNPs. 
SNPs within the drug targets of the TB genome can confer resistance to specific first- and 
second-line drugs. This project specifically focuses on the katG, inhA, rpoB, and gyrA genes as they 
contain the most commonly occurring drug resistance mutations [5]. Mutations in the sequence of 
katG, a catalase-peroxidase enzyme, cause decreased activation of the prodrug INH, the most widely 
used first-line drug against tuberculosis, and contribute to 75-90% of the strains resistance to INH 
[5, 42].  Mutations in the promoter region of the drug target gene inhA, which functions as a 
NADH-dependent enoyl-acyl carrier protein, account for an additional 10% of strains resistance to 
INH [5, 42].  Mutations in the beta subunit of RNA polymerase, encoded by the rpoB gene, are 
present in 90% of strains that are resistant to RIF, another first-line drug used to treat TB [5, 42].  
Resistance to fluoroquinolones, a second-line anti-tuberculosis drug, is conferred by 
mutations in DNA gyrase, an enzyme involved in regulating the supercoiled topology of double-
stranded DNA (dsDNA) [5]. DNA gyrase consists of two alpha and two beta subunits encoded by 
gyrA and gyrB respectively [5]. Over 90% of fluoroquinolone resistant M. tuberculosis strains have 
mutation in these two genes, contributing to XDR TB [5].  Currently other members of the Rohde 
lab are developing MDR sensors for INH and RIF. This project specifically focuses on the 
development of an XDR assay that will identify resistance conferring SNPs on the gyrA gene [5]. 
Mutations within a highly conserved area of gyrA known as the quinolone-resistance-determining-
region (QRDR) have been shown to confer fluoroquinolone resistance on TB [5]. Codons 90 and 94 
of gyrA contain the most prevalent resistance-conferring mutations, particularly A90V 
(GCGGTG) and D94G (GACGGC) [5]. The goal of one of the aims of this project is to 
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design sensors that will identify the D94G mutation in gyrA. The development of a molecular assay 
with the ability to detect these SNPs indicative of a drugR profile could enable the rapid and efficient 
treatment of TB. 
Current Diagnostic Methods 
Rapid and affordable POC detection of tuberculosis and drug resistance is imperative to 
improve treatment and control the spread of TB. Current methods of detection include microscopy, 
culture and drug susceptibility testing, as well as molecular testing [43]. Sputum smear microscopy, is 
the most widely used method to detect infectious TB, especially in low and middle income countries 
because it takes advantage of inexpensive equipment and materials. This diagnostic method is 
accomplished through the collection and analysis of sputum specimens from persons suspected of 
having TB [10]. Due to the acid-fast nature of its cell wall, tuberculosis bacilli are able to be stained 
using the Ziehl-Neelson staining method and examined microscopically [22]. However, acid-fast 
organisms other than M. tuberculosis may appear [10]. Less than 50% of cases are usually detected 
because an excess of 10,000 microbes/mL of sputum are needed to visualize the bacilli and many 
positive TB patients have been shown to have negative smears (i.e. children and co-infected-HIV 
patients) because of their pauci-bacillary sputum samples (low bacilli numbers in sputum below 
detection ability of assay) [10, 22]. The pathogen may also be undetectable with this method 
depending on how advanced the infection is, because some Mtb lose their acid-fastness. Other 
limitations of smear microscopy include its time consuming protocol and inability to detect drug 




 The culture methods may be used in diagnosis of Mtb but further testing is needed to 
differentiate Mtb from Non-tuberculosis Mycobacteria (NTM) and it requires highly technical 
expertise and expensive machinery [43]. It is important to specifically identify the M. tuberculosis 
species because other NTM may require their own specific treatment regimens [46]. This method is 
also at a disadvantage because it can take up to 6 weeks to produce results, allowing for the 
possibility of inappropriate treatment if patients are started on a typical treatment regimen before 
results are obtained. If the patient is indeed infected with MDR-TB, the treatment will be ineffective 
allowing the spread and amplification of drug resistant TB in the meantime [45]. Drug susceptibility 
testing, through the culture-based observation of growth or inhibition in a medium containing 
antituberculosis drug, can provide a definite diagnosis of drug-resistant TB but its methods are also 
costly and not readily available in high burden areas [43, 47]. 
Molecular testing involves examining the DNA of specific genes that are known to cause 
drug resistance if mutated [12]. Methods such as conventional DNA sequencing, pyrosequencing, 
real-time PCR, and line-probe assays are the optimum diagnostic methods available due to their 
rapid, accurate, and safe detection strategies however these techniques are still accompanied by 
limitations [43]. All of the current molecular diagnostics are extremely labor intensive and expensive. 
DNA sequencing and pyrosequencing require very complex machinery and costly reagents that may 
not be readily available in POC environments [12]. Real-time PCR techniques such as the fully 
automated GeneXpert MTB/RIF have been proven to rapidly detect the presence of M. tuberculosis 
as well as identify rifampin resistance. It does so by employing multiple fluorescent molecular 
beacons to detect the presence of rpoB mutations, which confer 95% of rifampin resistance [5]. Line 
Probe Assays, such as the Hain Line Probe Assay MRBDRplus, employ immobilized membrane-
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bound probes that result in a color change upon binding to specific PCR products that are able to 
identify mutations in the rpob, katG, and inhA genes that confer resistance to RIF and INH [5, 12]. 
However, both of these molecular methods can yield inaccurate results due to silent mutations, 
require multiple beacons/probes, and, besides being very expensive, are not amenable for POC use  
[12, 43]. The pitfalls of these current techniques reinforce the urgent need for more efficient 
diagnostics and drug susceptibility testing (DST) that can be used to detect drug resistance and 
facilitate prompt, appropriate treatment plans. This project seeks to address the lack of quick, 
specific, and affordable diagnostics through the development of a novel diagnostic technology based 
on deoxyribozyme (DNAzyme) sensors for detection of TB and identification of drug resistance.  
DNAzyme Sensor Technology for specific detection and differentiation of nucleic acids 
Deoxyribozymes (DNAzymes) are catalytically active DNA enzymes that were identified by 
in vitro selection [48]. Originally, DNAzymes were designed as a single DNA strand consisting of a 
catalytic domain flanked by two substrate recognition arms [49]. In the presence of a specific analyte, 
the DNAzyme folds into a catalytically active secondary structure that hybridizes to the analyte 
DNA and cleaves a ribonucleotide within the middle of the sequence. However, the length of the 
original DNAzyme contributes to its stability, enabling it to hybridize to mismatched sequences and 
and therefore preventing its specificity [50]. A binary approach, developed by our collaborator, Dr. 
Dmitry Kolpashchikov, divides the DNAzyme into two parts, splitting the catalytic core in half, and 
allowing for extremely selective nucleic acid recognition and improved sensitivity of SNP detection 
down to a single base substitution [50]. 
We take advantage of this binary DNAzyme design to create DNAzymes, specific for Mtb 
analytes, which will have the ability to distinguish drugR-conferring SNPs. As shown in Figure 1, the 
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binary DNAzyme assay consists of a substrate, analyte, and two sensor strands each containing an 
analyte binding arm, half of the catalytic core, and a substrate binding arm. The substrate is a dual-
labeled synthetic oligonucleotide with a fluorophore on the 5’ end and a quencher at the 3’ end. 
When a specific analyte is present, the sensor strands will bind adjacently on the analyte. After 
binding the analyte, the sensors will then bind the substrate, reforming the catalytic core, and 
subsequently cleave the substrate. This cleavage separates the quencher and the fluorophore 
resulting in the production of a fluorescent signal/output [51].  
 
Figure 1: Binary DNAzyme Sensor Assay 
Deoxyribozyme sensors can be used for the detection and differentiation of DNA/RNA analytes. This binary 
DNAzyme approach splits the catalytic core and allows for the attachment of two short sequences complementary to 
the analyte binding arms. In the presence of a DNA/RNA analyte the substrate will be cleaved releasing a 
fluorescent/visual output. A) Binary DNAzyme sensor bound to a matched analyte. The analyte binding arms hybridize 
to the matched analyte allowing the formation of the catalytic core.  This results in cleavage of the substrate and the 
production of a fluorescent output. B) Binary DNAzyme sensor in the presence of mismatched analyte. Due to the 
presence of a SNP, one of the analyte binding arms will be unable to bind and the catalytic core cannot form. Therefore, 
there will be no cleavage of the substrate. 
DNAzymes provide several advantages for the specific and sensitive detection of 
DNA/RNA analytes. Their catalytic activity allows for activation of approximately eighty substrate 
molecules/minute, resulting in signal amplification, unlike the Gene Xpert and molecular beacon 
based approaches that are only able to bind a single fluorescent probe/analyte molecule [52]. The 
simple design requires only two short DNA strands for each new analyte designed because the 
double-labeled reporter substrate is universal for all analytes, reducing the cost of this technology 
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significantly [50, 53]. The combination of a short analyte binding arm and a long analyte binding arm 
allows for high sensitivity and selectivity [50]. The presence of a single SNP prevents the binding of 
the short analyte binding arm, inhibiting the activation of the DNAzyme and substrate cleavage [50]. 
Longer oligonucleotides are more likely to bind mismatched DNA. The overall goal is to create an 
assay which combines Polymerase Chain Reaction (PCR) and DNAzymes to identify drug resistance 
conferring SNPs. 
The goals for the project are as follows: 
Objective 1: To construct a panel of drug resistant (drugR) nonpathogenic M. bovis BCG.  
MDR-TB is dangerous, therefore creating a library of attenuated drugR Mycobacterium bovis 
BCG allows us to safely test different DNAzyme sensors on real bacteria. This will be accomplished 
by cloning regions surrounding the SNP of interest, making the mutation by QuickChange site 
directed mutagenesis, and transforming it into wild-type M. bovis BCG, and selecting for resistance. 
This project will focus on drugR conferring mutations in the gyrA gene.   
Objective 2: To design a multiplex PCR that will amplify chromosomal regions necessary for TB detection and drug 
susceptibility testing (DST) 
The overall goal is to use six sets of primers to simultaneously amplify regions of the 
genome that will be used later in the multiplex assay for the species-specific detection of TB and 
determination of a drug susceptibility profile based on the presence of SNPs. Nucleic acid 
amplification (NAA) through PCR is imperative to increase the sensitivity of the assay, because the 
current limit of detection is not sensitive enough to detect a single copy on the chromosome. The 
PCR conditions will be optimized to achieve optimal specificity, yield, and speed.  
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Objective 3: To design and optimize DNAzyme sensor assays of PCR analytes for detection and DST of Mtb. 
The binary design of the DNAzyme assay allows for improved sensitivity of SNP detection. 
The sensors will be optimized to balance selectivity and sensitivity. This will be accomplished by 
constructing sensors that will discriminate between single SNPs and still produce a good signal. The 
limit of detection (LOD) and specificity will be determined. The sensors will be tested on synthetic 
analytes, DNA from MDR- and XDR-TB clinical isolates. Combining the DNAzyme sensors with 







 Originally it was thought that single stranded DNA (ssDNA) was the preferred DNAzyme 
analyte. To generate the ssDNA analyte, we explored the use of Linear After The Exponential PCR 
(LATE-PCR), an asymmetric PCR method which employs unequal concentrations of primers that 
run logarithmically until one of the primers run out [54].  
Our preliminary data comparing LATE-PCR and conventional symmetric PCR revealed that 
the generation of ssDNA is not necessary for detection by DNAzymes (data collected by B. 
Rosenkrantz not shown). This is advantageous because asymmetric PCR requires many cycles while 
the symmetric approach can be completed in less cycles, meaning less time. As shown in Figure 2, 
using the symmetric PCR we were able to detect as few as 50 pg of DNA or 5000 colonies forming 
units (CFU). 
 
Figure 2: Limit of Detection for DNAzyme detection of Symmetric PCR Analytes.   
Serial dilutions of template DNA (x-axis) were amplified by 30-cycles of symmetric PCR and detected by binary 
DNAzyme assay.  Wild-type specifc rpoB binary sensors were used for the detection of PCR products.  The Signal to 
Background (S/B) ratio (y-axis) shows that Symmetric PCR (30 cycles) and  DNAzyme sensors can detect as little as 


























General Overview of Bacterial Cell Culture 
 NEB 10-Beta Competent Escherichia coli (E. coli) High Efficiency and electrocompetent 
Mycobacterium bovis bacillus Calmette-Guérin (BCG) were used to conduct the experiments for this 
project. E. coli was used to amplify plasmids containing genes and DNA fragments PCR amplified 
from CDC1551 chromosomal Mtb DNA (20 ng/μL) during cloning [55]. E. coli was also used as a 
DNA source for transformation into M. bovis BCG for the development of a panel of 
nonpathogenic drug resistant strains.  
 E. coli was grown up in Luria broth (LB) within a 5 mL culture tube overnight at 37°C, 
shaking at 250 revolutions per minute (rpm). When constructing plasmids, 50 μg/mL of the 
antibiotic Kanamycin (Kan) was used to select clones containing the vectors of interest.  
Creating a panel of drug resistant (DrugR) nonpathogenic M. bovis BCG. 
The conservation of DNA between Mtb and the vaccine strain M. bovis BCG has enabled 
BCG to be used as a surrogate model for Mtb. Designing a panel of nonpathogenic BCG strains 
with specific SNPs that confer distinct drugR will provide a safe template that has the same genetic 
background as the real drugR Mtb. The variety of strains containing drugR mutants will be used to 
develop an assay that can differentiate individual mutations in a single sample. This project 
specifically focuses on the development of a strain containing a drugR conferring gyrA D94G 




Construction of gyrA 94 WT Fragment 
First, primers, shown in Table 2, were designed to specifically amplify a 2 kilobase (kb) gyrA 
gene fragment using “ApE – A plasmid Editor”, a molecular biology program used for sequence 
editing and design, and information from Mycobacterial DNA databases including the “Myco DB - 
xBASE” and TbDb databases [56-59]. Then, amplification of the gyrA gene insert was achieved by 
Polymerase Chain Reaction (PCR). The DNA is PCR amplified through a few general steps. First, 
the double stranded DNA must be denatured to separate the complementary strands of DNA by 
heating it to 95°C [60]. After this primary denaturation, a secondary denaturation is necessary to 
ensure complete separation [60]. The third step is an annealing phase in which the temperature 
lowers to allow the DNA primers to hybridize to their complementary sites on the DNA template 
[61]. The annealing temperature is dependent on the melting temperature (Tm) of the specific 
primers used [61]. The primers are then extended using DNA polymerase, an enzyme that catalyzes 
the synthesis of new DNA by adding nucleotides onto the annealed primer that are complimentary 
to the template DNA [60]. This step is conducted at a temperature optimal for the Phusion® DNA 
polymerase, allowing the enzyme to replicate the strand of template DNA. These three steps are 
repeated for many rounds to enable the exponential amplification of the DNA of interest. Lastly, 
there is a final extension step that allows for the most recent DNA copies to finish replicating [60].  
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The protocol followed was “PCR Protocol for Phusion® High-Fidelity DNA Polymerase” 
[62]. The reaction was ran in a temperature-controlled BioRad thermocycler, allowing for the proper 
denaturation and annealing of DNA fragments and enabling the Phusion® enzyme to activate at 
specific temperatures. The typical Phusion PCR Cycle used in shown in Table 1. The gyrA specific 
primers were used to clone 1.0 kilobase (kb) on both sides of the well-characterized gyrA SNP 
location.  
The reaction consists of a mixture containing buffers, nucleotides, primers, enzyme, and the 
DNA of interest. A typical PCR reaction contains 1.0 μL of template DNA (~20 ng/μL), 1.0 μL of 
forward primer (100 ng/μL), 1.0 μL of reverse primer (100 ng/μL), 5.0 μL of 5X GC Buffer, 0.25 
μL of Phusion® Enzyme, 0.5 μL of 10mM deoxynucluotides (dNTPs), and 16.25 μL of sterile 
water, for a total volume of 25 μL per reaction tube. After amplification, the presence and correct 
size of the PCR products were verified using agarose gel electrophoresis. For detection, 5.0 μL of 
the PCR product was resolved on 1% agarose gel using TAE buffer and stained with Promega Gel-
red.   
TOPO Cloning 
Once the insert containing the amplified wild type (WT) gyrA fragment was obtained, a 
plasmid containing the WT sequence encompassing SNPs in the target gene was constructed. This 
was accomplished using Zero Blunt® TOPO® cloning, an extremely efficient, 5-minute, one-step 
cloning process for the direct insertion of blunt-ended PCR products into a plasmid vector. The 
enzyme, Topoisomerase, is linked to the end of the linearized TOPO vector and catalyzes the 
ligation of an insert into the vector [63, 64]. This process is efficient because no ligase, post-PCR 
procedures, or PCR primers containing specific sequences are required. The TOPO process is also 
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advantageous because it allows direct selection of recombinants. The pCR4Blunt-TOPO® plasmid 
contains a KanR gene that is used to select for colonies that have incorporated the vector and cells 
containing the non-recombinant vector, lacking the resistance, will be killed upon plating [65]. 
The TOPO Cloning reaction mixture consists of 1.0 μL of the TOPO Cloning vector, 1.0 
μL of a salt solution, 2.0 μL of the 2 kb gyrA PCR product, and enough sterile water was added to 
bring the final volume up to 6.0 μL. The reaction was incubated for 5 minutes at room temperature 
25°C then placed on ice. 2.0 μL of this TOPO Cloning reaction mix was pipetted into a vial of 
competent E. coli, mixed gently, and incubated on ice for 30 minutes. After incubating, the cells were 
heat shocked at 42 °C for 30 seconds and immediately transferred to ice for recovery. 250 μL of 
room temperature SOC medium was added and the tube was capped and shook horizontally at 37°C 
for 1 hour. 10-50 μL of the transformation was spread on a Kan antibiotic selective plate and 
incubated at 37°C overnight.   
Colonies present on the pTOPO-gyrA transformation were PCR screened using M13 
forward and reverse primers (100 ng/μL), shown in Table 2, to verify that the insert was present in 
the vector. Colony PCR screening involves bacterial lysis and DNA extraction for use in a PCR 
reaction. To lyse the bacteria, an isolated colony was labeled, picked from the plate, and added to a 
tube containing 20 μL of deionized water (diH2O). The tube was boiled at 100°C for 10 minutes and 
centrifuged at 13,000 rpm for 10 minutes to pellet the bacterial debris. 2.0 μL of the resulting 
supernatant was used as the DNA template for PCR amplification. Positive colonies were identified 
based on the amplification of the band at an anticipated size of 2 kb on a 1% agarose gel.  
The positive colonies were picked and grown overnight in 7 mL LB broth containing 7.0 
μg/mL Kan to amplify the DNA. The plasmid was then isolated using the Plasmid Mini-Prep 
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Protocol. [66] First, the pellet was harvested from the E. coli culture using centrifugation. The 
supernatant was discarded and the pellet was suspended in 250 μL of an RNase A Buffer (100 
μg/mL) [66]. After adding 250 μL of MX2 Buffer, the tube was gently inverted 4-6 times, and 
allowed to incubate at room temperature for 5 minutes until the solution became clear [66]. 350 μL 
of MX3 Buffer was then added, the tube was inverted 4-6 times afterwards, and centrifuged at 
12,000 rpm for 10 minutes [66]. The supernatant was then transferred to a spin column and 
centrifuged at 4,000 rpm for 1 minute and the flow through was discarded. 500 μL of WS Buffer 
was added to the spin column and centrifuged for 1 minute, discarding flow through [66]. This was 
done twice to wash the mixture. The resulting mixture was centrifuged again to remove residual 
ethanol and the column was placed in a new microcentrifuge tube. 50 μL of EB Buffer was added to 
the membrane and, after sitting for 5 minutes, the tube was centrifuged at 12,000 rpm for 1 minute 
to elute the DNA [66]. The concentration of the resulting mini-prep DNA was measured using a 
Nanodrop spectrophotometer and the plasmid was submitted to Genewiz for sequencing to verify 
the presence of the 2 kb gyrA fragment. Then glycerol stocks were made to store aliquots of the 
DNA by inoculating 500 μL of 50% glycerol with 1.0 mL of the culture. The purified plasmid was 
then used as a template for QuikChange mutagenesis to create the gyrA mutant (MT).  
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Table 2: Cloning Primers 
Cloning primers 
Locus Primer Sequence (5' to 3') 
Size 
(bp) 
Tm Product (bp) 
gyrA 2kb 
gyrA_2kb_F ATTGCCGTTCCACGGATC 18 66 
2000 
gyrA_2kb_R GGGCGATATCGACGGTCT 18 65 
gyrA 94 QuikChange 
gyrA_QC_F CGATCTACGGCACCCTGG 18 67 
 gyrA_QC_R CCAGGGTGCCGTAGATCG 18 67 
M13Long  
M13L_F TGTAAAACGACGGCCAGTGAATT 23 68 
?299 
M13L_R CAGGAAACAGCTATGACCATGAT 23 64 
 
 
Figure 3: Creation of a drugR BCG strain using TOPO Cloning and Site-Directed Mutagenesis 
A) gyrA specific primers were used to clone 2 kb fragment containing a gyrA gene and Phusion PCR was used to amplify 
the WT gyrA 94 gene of interest within CDC1551 Mtb DNA (20 ng/μL). B) TOPO cloning was used to insert the 2 kb 
WT gyrA 94 fragment into the pCR4Blunt-TOPO plasmid containing KanR antibotic resistance marker. C) QuikChange 
PCR primers designed to contain the D94G SNP in the center of their sequences were used for the rapid insertion of 
the mutation. D) Once the mutation was inserted, the 2 kb PCR Primers were used to amplify the gyrA mutation  E) 
Butanol Precipitation was used to prepare the MT product for tranformation into BCG. F) After making competent 
cells, electroporation was used to transform the 2 kb linear PCR product containing the mutation into WT BCG. G) The 




QuikChange Site-Directed Mutagenesis 
After successfully TOPO cloning, methodology similar to QuikChange (QC) Site-Directed 
Mutagenesis was performed to insert the mutation, as shown in Figure 3. This was accomplished 
through a series of steps. First, individual mutagenic primers needed to be designed. Both the 
forward and reverse primers were designed to contain the gyrA D94G SNP of interest and to anneal 
to the same sequence on opposite strands of the plasmid, as shown in Table 2. The desired mutation 
was designed to be in the middle of the primers with ~10-15 nucleotides of the correct sequence on 
each side [67]. This reaction followed the protocol by Strategene, in which 2.0 μL of lysate from 
colonies containing the gyrA insert was combined with 1.0 μL of each gyrA Mutation QuikChange 
forward and reverse primer (100 ng/μL), 0.25 μL of Phusion® polymerase, 0.5 μL of dNTP’s, 5.0 
μL of 5X G.C. Buffer, and brought to a final volume of 25 μL using 16.25 μL of diH2O. The 
thermocycler PCR settings used for the QuikChange are shown in Table 3. 
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After performing the QuikChange PCR and verifying the successful amplification and size of 
the plasmid on a 1% gel, 1.0 μL of Dpn 1 restriction enzyme was added to the positive 
QuikChanged PCR sample, mixed thoroughly, and incubated for 1 hour at 37°C to digest the 
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nonmutated (parental) supercoiled dsDNA. Failure to do so results in a high false-positive rate of 
pTOPO-gyrA KanR colonies. 
After thawing an aliquot of 10-beta Competent E. coli cells, 4.0 μL of digested gyrA Mutant 
QuikChanged fragment was added. The cells incubated on ice for 30 minutes and were then heat 
shocked for 45 seconds at 42°C. After recovering on ice for 5 minutes, 250 μL of SOC medium was 
added and the cells were shaken for 1.5 hours to recover. Then, the entire volume of the 
transformation reaction was plated on LB-Kan (50 ug/μL) agar to select for antibiotic resistance and 
incubated overnight at 37°C.  
The colonies that grew were PCR screened for the insert of interest using M13 forward and 
reverse primers and verified on a 1% agarose gel. The PCR products of the E. coli colonies 
determined to contain the insert of interest were then prepared for direct sequencing using a PCR 
clean-up method that removes excess dNTPs and unincorporated primers from the PCR mixture. 
The PCR mixture was incubated at 37°C for 20 minutes in an Exo-SAP mixture consisting of 
Antarctic alkaline phosphatase, buffer, exonuclease (20 units/μL), and diH2O, to purify the DNA. 
The pure DNA was then sent for sequencing to determine if the correct mutation was present. The 
sequence was analyzed using ApE to align the mutated gyrA D94G sequence with the original WT 
gyrA sequence to verify that the correct mutation was present.  
Transformation into Wild Type BCG 
Once the mutated gyrA PCR product was amplified and the sequence was verified, butanol 
precipitation was performed to prepare the product for transformation into wild type BCG. This 
method removes salt from the ligation buffer to improve transformation efficiency. 10 μL of 
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unsaturated n-Butanol was used to precipitate every 1.0 μL of PCR reaction. The mixture was spun 
down in at 13,000 rpm for 5 minutes to remove supernatant. The tube was then washed with 100 μL 
of 70% ethanol and centrifuged for 5 more minutes to further remove any leftover supernatant. A 
speed vacuum was used to dry the pellet and then the pellet was suspended in 10 μL of water. The 
concentration of the MT gyrA 2 kb PCR product was then quantified using the Nanodrop 
spectrophotometer. 
30 mL of M. bovis BCG was pelleted with a 20 mL 10% glycerol wash to rid of excess salt. 
This was repeated in smaller and smaller increments until 1.0 mL of BCG was left. Then, 2.0 μg of 
gyrA MT DNA was transformed into 100 μL of electrocompetent BCG cells. The electroporation 
was accomplished in a 2.0 mL cuvette using the Biorad GenePulser Xcel Microbial System at 250 
Volts, 25 μF, and 1,000 Ω. After shocking the cells, they were placed in 5 mL 7H9 and allowed to 
recover for 3 days.   
 After the recovery, 2 mL of electrocompetent drugR BCG was plated on 2 μg/mL 
Ciprofloxicin (Cipro) LB agar to select for resistant colonies that have incorporated the SNP-
containing DNA. Colonies were picked at 3 weeks and grown in 5 mL of 7H9 media. Then after 
growing for another 3 weeks, a well-established method of nucleic acid isolation from mycobacteria 
known as a hexadecyltrimethylammonium bromide (CTAB) treatment, was used to purify the DNA 
[68]. Once purified, the DNA product was sent for sequencing to confirm the transformation. The 
resulting engineered drugR M. bovis BCG DNA was used as a template in the multiplex PCR which 




Design of the Multiplex PCR 
The goal of this aim is to develop a multiplex PCR with the ability to simultaneously amplify 
six targets, including MTC-specific loci and drugR loci for MDR and XDR-TB, in a single reaction. 
The multiplex PCR will be combined with DNAzyme sensors in an assay to specifically detect TB 
and identify first and second line drugR in a single sample. PCR amplification is important because 
the current limit of detection is not sensitive enough to detect a single copy on the chromosome.  
Primer Design 
First, primers were designed to specifically amplify the regions of interest. For species 
specific identification of TB, two of the primer pairs were designed to target the 16S and 23S rRNA 
genes, which are completely identically in BCG and TB. The targeted regions of the 16S and 23S 
rRNA genes are hypervariable regions unique to Mtb and therefore are capable of distinguishing TB 
and BCG from other members of the Mycobacterium tuberculosis complex (MTC). 
Then 4 other primers pairs were designed to target genes associated with drugR. As stated in 
the background section, the target genes, gyrA, katG, rpoB, and inhA, were picked to cover the most 
common SNPs conferring resistance to first and second line drugs. Mutations in inhA and katG 
both confer isoniazid resistance (InhR), a frontline drug for TB.  Mutations in rpoB confer rifampinR 
(RifR), another first line drug, and gyrA mutations confer fluoroquinoloneR, a second-line drug used 
in TB treatment [69]. The 12 multiplex primers that were designed are shown in Table 4 with their 
corresponding locus, sequence, nucleotide length, and Tm. The 6 multiplex PCR products are 
shown in Table 5 with their description, amplicon size, and mutations. The amplicons were designed 
to be approximately 50 base pairs apart to allow for gel resolution.  
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Table 4: Multiplex PCR Primers 
Locus Primer Sequence (5' to 3') Size (bp) Tm 
inhA 
inhA_F1 CCGGAAATCGCAGCCA 16 64 
inhA_R1 CGGTTTCCTCCGGTAACCA 19 65 
rpoB 
rpoB_F GTCGCCGCGATCAAGGAGTT 20 71 
rpoB_R CCCTCAGGGGTTTCGATCGGG 21 74 
16S rRNA 
16s_rRNA_F1 GCGATGCCGCGAGGTTA 17 66 
16s_rRNA_R1 ACTTCGTCCCAATCGCCG 18 66 
katG 
katG_F1 ATGGCCATGAACGACGTC 18 65 
katG_R1 GTGTATTGCCAAGCGCCA 18 66 
gyrA 
gyrA_F1 GACTCGCTCGACCGGATC 18 66 
gyrA_R1 GGGCTTCGGTGTACCTCATC 20 66 
23S rRNA 
23s_rRNA_F1 CTCTGCTGCCAAGAAAAGCC 20 66 
23S_rRNA_R1 CAGGTCGGAACTTACCCGAC 20 66 
 










Species specific TB 
detection 
410 Multiple 
inhA isoniazidR 149 
Promoter -15 nt 
C→T 
katG isoniazidR 299 
Codon 315 
AGC→ACC 
rpoB rifampinR 200 Codon 526 




Philisa® Thermal Cycler PCR Optimization 
Conventional PCR is very time consuming due to slow ramp rates. In an effort to develop a 
fast and convenient assay, the Philisa® Thermal Cycler PCR instrument was used to dramatically 
reduce amplification time by utilizing extremely quick temperature ramp times and novel reaction 
tubes designed for more efficient heat transfer [70]. The rapid thermal cycler is used with a 
PhilisaFAST™ DNA polymerase, an enzyme designed to facilitate fast extension times.    
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Each 25 μL reaction contained 1.0 μL of CDC1551 chromosomal Mtb DNA (20 ng/μL), 12 
μL of 10 μM Primer Stock, 5.0 μL of FASTBuffer, 4.0 μL of 2.5 μM dNTPs, 0.5 μL of 
PhilisaFAST™ Polymerase, and 2.5 μL of diH2O. This 10 uM primer stock contained 1.0 μL of 
each of the twelve forward and reverse primers (10 μg/μL) needed for the amplification of the 23S, 
16S, inhA, rpoB, gyrA, and katG genes, making 400 nM the final concentration of each primer within 
the 25 μL PCR reaction. The multiplex PCR products were verified for clear differentiation and size 
on a 2% agarose gel, also using a “no-DNA” control to determine contamination. 
 The PCR was optimized to obtain maximum specificity and yield. Switching from 
conventional PCR methods to the rapid Philisa PCR strategy required optimization of the thermal 
cycler parameters to determine the most efficient duration for annealing and number of cycles. To 
determine the most efficient annealing temperature that provides a balance between maximum yield 
and minimum mis-priming, the annealing temperature was tested in 2 degree intervals. Then the 
number of PCR cycles that would yield the most DNA was determined by running reactions with 
30, 40, and 50 cycles. To develop the most time efficient protocol, the timing of each step of the 
PCR reaction was adjusted to the fastest time that would still amplify the most DNA. The PCR 
conditions shown in Table 6 were determined to be the most optimal, producing an efficient 
protocol that is just over 30 minutes long. The PCR products were ran on a 2% agarose gel to verify 
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temperature. 
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DNAzyme Sensor Assay 
General Assay Design  
The assay was designed to identify the presence of TB and for the detection of MDR SNPs. 
The assay designed for gyrA, shown in Figure 4, consists of a substrate, analyte, and two sensor 
strands, each containing an analyte binding arm, half of the catalytic core, and a substrate binding 
arm. The substrate is a dual-labeled synthetic oligonucleotide with a FAM fluorophore on the 5’ end 
and a quencher (Blackhole Quencher 1 (BHQ1)) at the 3’ end. 
 
Figure 4: Schematic diagram of the gyrA 94 wild-type DNAzyme sensor  
Binary DNAzymes specific for the WT Mtb gyrA 94 and MT Mtb gyrA D94G analytes were designed. The WT Mtb gyrA 
94 analyte strand is shown with the SNP of the MT strand above it. The DNAzyme consists of a substrate (orange), 
specific analyte (black), and two sensor strands. Two A strands (Dza) were designed, one complementary to the WT 
analyte and the other complementary to the MT, each containing an analyte binding arm (pink), half of the catalytic core 
(purple), and a substrate binding arm (purple). Only one version of the B strand (Dzb), complementary to the WT 
sequence, needed to be designed, also consisting of an analyte binding arm (red), half of the catalytic core (green), and a 
substrate binding arm (green). The Mz substrate is a dual-labeled synthetic oligonucleotide with a FAM fluorophore on 
the 5’ end and a quencher (BHQ1) at the 3’ end. When the specific gyrA analytes are present, the sensor strands will bind 
adjacently on the analyte. After binding the analyte, the sensors will then bind the substrate, reforming the catalytic core, 
and subsequently cleaving the substrate. This cleavage separates the quencher and the fluorophore resulting in the 




The substrate is a dual-labeled synthetic oligonucleotide with a FAM fluorophore on the 5’ 
end and a quencher (Blackhole Quencher 1 (BHQ1)) at the 3’ end. This project specifically focuses 
on designing an assay to detect drugR conferring SNPs within the gyrA gene. Sensors for targeted 
regions of 16S and 23S ribosomal RNA were chosen for the species-specific identification of Mtb 
because their sequences are conserved in both TB and BCG, yet not conserved in other strains of 
Mycobacteria. Multiple sensors will increase the specificity of the assay by identifying both the 16S 
and 23S rRNA regions in the mycobacteria [15, 71]. The sensors were tested against multiple 
templates: a negative control to detect contamination, synthetic analytes that are a perfect match to 
the sensors, CDC1551 Mtb DNA, DNA from the gyrA D94G BCG constructed in Objective 1, and 
purified DNA containing the gyr94 SNP from XDR-TB, provided by Dr. Susanne Homolka and Dr. 
Stefan Niemann at the National Mycobacteria Reference Center in Borstel, Germany. 
Sensors were designed to detect the gyrA D94G (GACGGC) SNP and tested for optimal 
balance of selectivity and sensitivity. This was accomplished by constructing the short and long 
analyte binding arms with different lengths and target Tm’s to allow for sensitivity and selectivity. 
The short arm is designed to hybridize to the region overlapping the SNP. The binary DNAzyme 
sensors were tested against a matched analyte and a mismatched analyte to determine specificity. The 
specificity was optimized by testing the sensors with short binding arms of differing lengths and 
Tm’s. After designing sensors for the identification of the gyrA D94G SNP, a LOD assay of the 
gyrA WT and MT sensors was completed to determine the sensitivity of the assay. A serial dilution 
of the synthetic analytes ranging from 1.0 nM to 12.5 pM, was used in multiple trials. The data was 
plotted to calculate a linear trend line and the equation used to determine the LOD was based on the 
average of 7 background samples + 3x(the Standard deviation of the 7 background samples). An 
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optimized assay combining multiplex PCR with DNAzyme sensors will enable the rapid, POC 
detection of drug resistance. 
Table 7: Assay Sensors 
The color coding and bolding refers to the following. Red: Analyte Binding Arm B. Blue: Analyte Binding Arm A. 
Green: Substrate Binding Arm B. Blue: Substrate Binding Arm A. Underline: catalytic core sequence. Bold: location of 





Substrate: AAGGTT-FAM-TTCCTCguCCCTGGGCA-BHQ     
        
A_16s_rRNA CACAAGACATGCATCCCGTACAACGAGAGGAAACCTT 52.6 19 
B_16s_rRNA TGCCCAGGGAGGCTAGCTGGTCCTATCCGGTATTAGACCC 50 20 
MTB_#_2 ACTGGGTCTAATACCGGATAGGACCACGGGATGCATGTCTTGTGGTGGAA 52 50 
MSMEG_#_2 ACTGGGTCTAATACCGAATACACCCTGCTGGTCGCATGGCCTGGTAGGGG 58 50 
MABS_#_2 ACTGGGTCTAATACCGGATAGGACCACACACTTCATGGTGAGTGGTGCAA 50 50 
        
A_23s_rRNA AGTAAACAGTCGCTCCTCACTGGTTACAACGAGAGGAAACCTT 48 25 
B_23s_rRNA TGCCCAGGGAGGCTAGCTTCTGCGACCGGATCCCGCTCCCACC 72 25 
MTB_23 GGTGGGAGCGGGATCCGGTCGCAGAAACCAGTGAGGAGCGACTGTTTACT 60 50 
MSMEG_23 GGCCCAAGCGTGAGTGGGTGGCACAAACCAGTGAGAAGCGACTGTTTACT 56 50 
MABS_23 TCCGTGAGCTGAACGAGGTCGCAGAGACCAGTGAGAAGCGACTGTTTACT 54 50 
        
A1_MT_gyrA TGCCCAGGGAGGCTAGCTCACCAGGGTGCCGTAG 68.8 16 
B1_gyrA CCAGGGCTGGGCCATGCGACAACGAGAGGAAACCTT 77.8 18 
gyrA_WT CTACGACACCCTGGTGCGCATGGCCCAGCCCTGG 70.6 34 
gyrA_MT CTACGGCACCCTGGTGCGCATGGCCCAGCCCTGG 73.5 34 
        
A2_gyrA_64* TGCCCAGGGAGGCTAGCTCCAGGGTGTCGTAGATCG 61.1 18 
A2_gyrA_62* TGCCCAGGGAGGCTAGCTCCAGGGTGTCGTAGATC 58.8 17 
A2_gyrA_61* TGCCCAGGGAGGCTAGCTCCAGGGTGTCGTAGAT 55.7 16 
B2_gyrA AGGGCTGGGCCATGCGCAACAACGAGAGGAAACCTT 72.2 18 
gyrA_WT2 CGATCTACGACACCCTGGTGCGCATGGCCCAGCCCT 66.7 36 




Experimental Setup  
The assay was first designed to test the designed sensors using a background control, WT 
synthetic analyte, and MT synthetic analyte. The assay was conducted in a 384-well plate. The 
analytes and RNAse free H2O were added directly to the wells first and a master mix containing the 
appropriate sensor strands was added last. The total volume of the assay was 60 μL per well. First, 
water was added to the wells. 15 μL of water was added to the sensor only (15 nM) background 
column and 9.0 μL of water was added to the analyte (1.0 nM) columns. Then 6.0 μL of each 10 nM 
synthetic analyte was added to the corresponding well.  
Then a master mix containing the substrate and specific adaptor strands was created, 
comprising 75% of the total volume of the assay. First, half the total volume in COL 2X Buffer  
(consisting of 50 mM HEPES, 50 mM MgCl2, 20 mM KCl2, 120 mM NaCl, 1% DMSO, and 0.03% 
Titon-X-100 reagents dissolved in sterile water) added. Then the amount of water needed to make 
up 75% of the total volume is calculated by subtracting the volumes of COL 2X Buffer, substrate, 
and sensor strands. The volume of substrate (200 nM) and adaptor strands (15 nM) necessary for 
the assay is dependent on the total volume of samples. The master mix is then thoroughly mixed 
and 45 μL is pipetted to each sample well. The assay is then sealed to prevent evaporation and 
incubated for 1 hour at 55°C. Once incubated, the assay is measured in the Biotek Synergy 4 
multimode plate reader using specific filter plus dichroic mirror optics at an excitation wavelength of 
485/20 and an emission wavelength of 528/20.   
Five multiplex PCR reactions were prepared, each utilizing a different DNA template: a 
negative “no DNA” control, WT CDC1551 DNA, WT gyrA 94 DNA, gyrA D94G MT BCG, and 
the gyrA D94G XDR-TB DNA. These multiplex PCR reactions were tested in an assay with gyrA 94 
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and 23S sensors. The gyrA 94 sensors were also assayed with WT and MT analytes and the 23S 
species specific sensors were assayed with Mtb, Msmeg, and Mabs synthetic analytes. Based on 
preliminary assays using the WT sensor, 25 μL was determined to be the amount of PCR mixture 
needed to yield robust signals. By aliquotting 25 μL and 19 μL of sterile H2O respectively, the 
background and analyte wells were also brought up to a total volume of 25 μL. The master mix 
concentrations were adjusted to a volume of 35 μL to keep the final volume at 60μL.  
Data Analysis – S/B ratios 
The data was analyzed to determine the performance of the sensors. This was accomplished 
by comparing the fluorescent output of the substrate to the fluorescent output of the background in 
a signal to background (S/B) ratio. The ability of the WT and MT sensors to differentiate between 
the WT and MT analytes, as well as the 5 multiplex reactions: negative “no DNA” control, WT 
CDC1551 DNA, WT gyrA 94 DNA, gyrA D94G MT BCG, and gyrA D94G XDR-TB DNA were 
analyzed. An optimized assay combining multiplex PCR with DNAzyme sensors will enable the 
rapid, POC detection of drug resistance. 
Alternative Approaches 
 Many potential problems involved with designing the panel of drugR BCG strains have been 
resolved through the use of the TOPO cloning kit. However, the transformation efficiency of Mtb 
and BCG is lower than that of E. coli so introducing an insert with the correct drug resistant 
mutation was difficult. The phenotype of the insertion is strong so if the transformation did not 
proceed successfully then the plasmid did not survive on the drug resistant selective plate. If we 
were unable to design the mutant of interest then we could have selected for the correct 
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spontaneous drugR mutation by plating on medium containing the corresponding antibiotic. Then, 
the colonies that were able to grow could be sequenced for the target loci to find the drugR strain. 
 The specificity, equal amplification efficiency, and optimization of the PCR conditions were 
challenging due to a number of different variables being involved. Through trial and error it took 
multiple optimizations to determine the correct number of cycles, annealing conditions, reagent 
concentrations needed for efficient amplification. Contamination of the negative PCR control also 
became problematic. This was attempted to be resolved through the use of a biosafety cabinet as 
well as DNase and RNAse free reagents and materials. Further multiplex PCR problems that may 
present in the future include how well the reaction will amplify DNA directly from clinical sputum 
samples and whether it will be sensitive enough. 
Designing the DNAzyme sensor assay as well as combining it with the multiplex PCR 
proved to be very challenging. Multiple optimization trials were required to determine the most 
efficient reagent volumes, assay temperature, and incubation time. Many trials were necessary to 
design sensors with optimal signal to background ratios while maintaining high specificity. The 
specificity was optimized by designing sensors with different TM’s, lengths, and SNP locations. 




The development of a novel diagnostic involved constructing a surrogate panel of safe drugR 
M. bovis BCG strains, designing a 12 primer multiplex PCR, and combining the multiplex PCR with a 
DNAzyme assay that can be used to identify TB and detect drugR. 
Construction of Safe Surrogate Panel of DrugR M. bovis BCG  
 In order to safely test the DNAzyme diagnostic assay, a nonpathogenic M. bovis BCG strain 
was engineered to contain the drugR-conferring gyrA SNP as detailed in the methods section.  Primer 
design and PCR amplification of the WT gyrA gene was necessary before the MT strain could be 
constructed. To verify the size of the WT gyrA PCR product on an agarose gel, a 1 kb Gene Ruler 
was used [72]. 3.0 μL of this standard was loaded into the first lane before the gel was run. An 
example of a gel that was imaged, after being stained in Gel Red dye, to verify the presence of the 
2000 bp WT gyrA insert is shown in Figure 5. The M13 primers in the second lane were used to 
confirm the correct size and the gyrA primers in the third lane show the insert. The upper bands are 




Figure 5: gyrA PCR Insert 
Example of the verification of the WT gyrA fragment PCR product DNA size on an agarose gel using both M13L and 
gyrA primers. 
 
After confirming the amplified DNA by running the plasmid on an agarose gel, the PCR 
products were TOPO cloned to insert the fragment into the pCR4Blunt-TOPO plasmid. The 
plasmid contained a KanR gene that enabled clones which incorporated the vector to be selected for 
upon plating on LB-Kan agar. Colony PCR was performed on the colonies that grew to screen for 
clones containing the pTOPO-gyrA plasmid. Once colony PCR screened, the positive colonies were 
grown overnight in an LB broth containing Kan to amplify the DNA and miniprepped to purify the 
DNA. After determining the DNA concentration using a Nanodrop spectrophotometer, the 
purified E. coli DNA was sent for sequencing to confirm that the WT gyrA fragment was inserted 
into the TOPO plasmid (data not shown). 
After successful cloning of the intended gyrA fragment was confirmed, QuikChange Site-
Directed Mutagenesis was used to insert the D94G mutation. First, specific primers containing the 
SNP in the center of their sequences were designed. Then, the WT DNA was amplified using the 
QC primers to amplify the mutant. The bacteria that incorporated the resulting plasmid were 
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selected for using the appropriate antibiotic. Colonies that grew were screened and verified on a gel 
to ensure that the correct plasmid was present (data not shown). In addition to visualization of the 
DNA on a gel, the plasmid was sequenced to confirm that the D94G mutant SNP was inserted into 
the WT plasmid. The sequence confirmation of gyrA D94G – TOPO plasmid is shown in Figure 6.  
 
Figure 6: Sequence confirmation of gyrA D94G – TOPO plasmid 
The gyr94 – TOPO plasmid was sent for sequencing and then aligned with the WT gyrA 94 sequence (top) to ensure that 
the correct mutation was present. The GACGGC mutation is shown in the red box. 
 
After the MT was verified, the PCR amplified and linear DNA fragment transformed into 
BCG using electroporation. The BCG that took up the MT fragment was selected for drugR on 
Ciprofloxacin antibiotic plates. The colonies that grew were colony PCR screened and verified on a 
gel to ensure that the PCR product was successfully double crossed into the BCG chromosome 
(data not shown). In addition to visualization of the DNA on a gel, the PCR product was purified 
using the PCR clean-up protocol discussed in the methods section and sent for sequencing to 
confirm that the drugR SNP was present.  The sequence confirmation of the gyrA D94G BCG strain 
is shown in Figure 7. 
 
Figure 7: Sequence confirmation of gyrA D94G BCG strain 
WT gyrA (top) aligned with MT gyrA D94G BCG (bottom) to verify that the mutation was inserted correctly. The 





Optimization of 12 Primer Multiplex PCR 
In order to develop an assay to specifically detect TB and identify first and second line drugR 
in a single sample, a multiplex PCR with the ability to simultaneously amplify particular targets 
including MTC-specific loci and drugR loci for MDR and XDR-TB, was designed in a single 
reaction.  Nucleic Acid Amplification, like PCR is needed to increase the sensitivity of the diagnostic 
assay, because the current limit of detection is not sensitive enough to detect a single copy on the 
chromosome. Then the multiplex PCR product was combined with DNAzyme sensors in an assay 
to specifically detect TB and identify first and second line drugR in a single sample.  
First, 6 primer pairs were designed to specifically amplify the regions of interest. 2 of these 
primers were designed to target the hypervariable regions of 16S and 23S rRNA that are only 
present in Mtb, enabling the assay to distinguish Mtb and the M. bovis BCG vaccine strain from other 
members of the MTC. The other 4 primer pairs were designed to target the gyrA, katG, rpoB, and 
inhA, genes which have been shown to contain the most prevalent SNP mutations that lead to first 
and second line drugR. The amplicons were designed to be approximately 50 base pairs apart to 
allow for gel resolution. 
Once designed, the PCR conditions were optimized to achieve optimal specificity, yield, and 
speed. This was accomplished using the Philisa thermocycler which facilitates rapid amplification 
through implementation of extremely fast ramp times and novel tubes allowing quick heat transfer. 
Multiple PCR trials were conducted to determine the most efficient primer concentration and 
cycling conditions. The optimized 10 uM primer stock contained 1.0 μL of each of the 12 forward 
and reverse primers (10 μg/μL) needed for the amplification of the 23S, 16S, inhA, rpoB, gyrA, and 
katG genes, making 400 nM the final concentration of each primer within the 25 μL PCR reaction. 
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The annealing temperature was tested in 2° intervals and 65°C was determined to yield the most 
PCR product. The number of denaturation-annealing-extension cycles was optimized through 10 
cycle interval trials and 50 cycles was shown to yield the most robust results. The multiplex PCR 
products were verified for clear differentiation and size on a 2% agarose gel, also using a “no-DNA” 
control to determine contamination. Figure 9 is an example gel image of the optimized 12 primer 
multiplex using each individual primer pair.  
  
Figure 8: 12 Primer Multiplex PCR for drugR detection with DNAzyme assay 
Agarose gel verification of the 12 Primer Multiplex PCR product compared to the PCR products of the 6 individual 
primer pairs. 
 
Creation of DNAzyme Sensor Assay 
To enable the rapid POC detection of drug resistant TB, a DNAzyme sensor assay of PCR 
analytes for the detection and DST of Mtb was designed and optimized. The sensors, shown in 
Table 7 of the methods, were designed to detect the gyrA D94G (GACGGC) that this project 
specifically focuses on and then tested for optimal balance of selectivity and sensitivity. This was 
done by constructing the short and long analyte binding arms with different lengths and target Tm’s 
to allow for optimal sensitivity and selectivity. Once designed, the binary DNAzyme sensors were 
first tested against a matched analyte and a mismatched analyte to determine specificity.  The 
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specificity was optimized by testing the sensors with short binding arms of the DNAzyme with 
differing lengths and Tm’s.  
The first round of gyrA sensor strands (A1 WT and A1 MT, and WT B1) tested were 
designed with analyte binding arms of about 16-18 nucleotides in length. The SNP was located in 
the sequence hybridized by the A analyte binding arm. Since the A strand was used for SNP 
discrimination, both a WT and MT A strand were designed and only a single WT B strand was 
needed. The A1-MT analyte binding arm was designed to contain the SNP near its center. The 
efficacy of the sensors was determined by comparing the signal of the specific strand to that of the 
nonspecific strand, this is referred to as the specificity ratio. A sensor is deemed efficient if it can 
yield a high specific signal and keep the nonspecific signal under 2. Through several assay trials, the 
A1-MT sensor strand, shown in Figure 10, proved to yield a high specificity ratio of about 4.3. This 
is found by dividing the average specific MT signal, 6.26, by the average nonspecific WT 
background signal, 1.45. However, new strands needed to be designed because the A1-WT sensor 
strand was not specific, having a low specificity ratio (data not shown). The specificity was 
optimized by shifting the sequences of the A and B analyte binding arms down 3 nucleotides and 
then 3 specific A strands, now referred to as A2, were designed by trimming the length of the 
shifted analyte binding arm. The newly designed A2 analyte binding arms were 18, 17, and 16 
nucleotides long and had corresponding Tm’s of 64, 62, and 61°C, shown in Figure 10. The A2 WT 
sensor with the highest Tm’s, 64°C, had the worst specificity, yielding a specificity ratio of 
approximately 1.56, found by dividing the average specific WT sensor signal, 8.02, but the average 
nonspecific MT signal, 5.12. The A2 WT 62 sensor had an average specific WT signal of 6.91 and an 
average nonspecific MT signal of 3.09, yielding a specificity ratio of 2.2. The sensor with the shortest 
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analyte binding arm and lowest Tm yielded the best specificity ratio of approximately 3.2: found by 
dividing the average specific WT signal, 6.28, by the average nonspecific MT signal, 1.98. This shows 
that shortening the arm, and therefore lowering the Tm, gave better specificity with only minimal 
loss of signal.  
The A1-MT and B1 strands were used in the assay to identify the MT and the A2-WT and 
B2 strands were used in the assay to identify the WT. The combination of these two sensor sets 
yielded the most efficient assay with the highest signal.  
  
Figure 9: Optimization of gyrA 94 WT sensor 
The specificity of the sensor strands were optimized by testing different analyte binding arm lengths and Tm’s. A1 refers 
to the first set of sensors developed and, through multiple trials, the A1-MT yielded a high, match to mismatch 
specificity ratio of approximately 6: 6.26(MT)/1.45(WT). The A1-WT sensor (not shown) proved to be nonspecific, with 
a low specificity ratio so a new set of sensors were designed by shifting the sequences by 3 nucleotides. New WT 
sensors, referred to as A2 were designed and optimized by trimming the analyte binding arm from 18 to, 17, and 16 with 
corresponding Tm’s of 64, 62, and 61°C (as shown above). A trend appeared in which the sensor’s specificity ratio 
increases as the length and therefore Tm, decreases. From the 8.02/5.13 specificity ratio of WT A2-64, 6.91/3.09 of WT 
A2-62, to the highest specificity ratio: 6.28/1.96 of the WT A2-61 sensor.  
 
After designing and optimizing sensors for the identification of the gyrA 94 SNP, a LOD 
assay of the gyrA WT and MT sensors was conducted using synthetic analytes to determine the 
sensitivity of the assay. A serial dilution of the synthetic analytes ranging from 1.0 nM to 3.125 pM, 
A2 - 64 A2 - 62 A2 - 61 A1 - MT
WT 8.02 6.91 6.28 1.45






























was tested in multiple trials. The data was plotted to calculate the linear trend line, shown in Figure 
10, and the equation used to determine the LOD was based on the average of 7 background samples 
+3(the Standard deviation of the 7 background samples).  
The calculated LOD is higher than expected. This may be due to variability in the S/B ratios 
of the 7 background samples (Data not shown). The LOD for the WT 61 sensor was calculated 
using the equation above to be 170 pM with an R2 value of 0.97. The signal of each reaction 
compared to the no analyte background control, known as the substrate to background (S/B) ratio, 
was used to analyze the data. At a concentration of 1 nM, the WT 61 sensor produced an average 
S/B ratio 3.95. At 500 pM, the S/B ratio decreased to an average of 2.8 and then decreased to 1.75 
at 250 nM. The S/B decreased to 1, unable to distinguish the analyte signal from the background, at 
an analyte concentration of 50 pM. The LOD for the WT 62 sensor was calculated to be 212 pM 
with an R2 value of 0.98. At a concentration of 1 nM, the WT 62 sensor produced an average S/B 
ratio 4.0. At 500 pM, the S/B ratio decreased to an average of 2.7 and to 1.9 at 250 nM. The S/B 
decreased to 1 at an analyte concentration of 50 pM. Further optimization of the WT sensors is 
needed for a more specific assay. 
The LOD for the MT sensor was calculated to be 108 pM with an R2 value of 0.98. At a 
concentration of 1 nM, the MT sensor produced an average S/B ratio 6.3. At 500 pM, the S/B ratio 
decreased to an average of 4.5.  At analyte concentrations of 250 and 50 pM, the S/B remained at 




Figure 10: gyrA 94 WT LOD 
Serial dilutions of the gyrA WT 61, WT 62, and MT synthetic analytes, from 1 nM to 3.125 pM (x axis), were ran with 
WT and MT-specific binary sensors and detected by the binary DNAzyme assay. The Average S/B ratio (y axis) shows 
that the MT DNAzyme sensor can detect as low as 108 pM of analyte and the WT 61 and WT 62 DNAzyme sensors 
can detect as low as 170 and 212 pM of analyte, respectively.  
The binary DNAzyme assay was tested with the multiplex PCR after verifying their 
successful PCR amplification on a 2% gel (data not shown). To determine the efficacy of our 
multiplex PCR-DNAzyme DST assay, ability to detect drugR SNPs in the multiplex PCR, the gyrA 
94 Multiplex PCR analytes from WT CDC1551, gyrA 94 BCG MT DNA, and gyrA 94 XDR-TB 
DNA was analyzed using WT and MT gyrA 94 sensors and 23s rRNA sensors. A negative “no 
DNA” multiplex PCR analyte was also used to verify contamination. The results are shown in 
Figures 11-13. 
Figure 11 shows the S/B ratios of the gyrA WT sensor, specifically the optimized A2-61°C 
WT sensor (background data not shown). The negative control, which was expected to have a low 
S/B ratio of approximately 2, was higher than expected due to contamination of the multiplex “no 
DNA” control.  The WT sensor reacted with the gyrA 94 Multiplex PCR analytes from WT 
y = 2.3635x + 701.97
R² = 0.9869
y = 2.3322x + 694.16
R² = 0.9851
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CDC1551 as predicted, yielding a high S/B ratio of 7.1. This was expected because the WT sensors 
are specific for the WT template. The WT sensor did not produce as much signal when combined 
with the Multiplex PCR analytes from the gyrA 94 BCG MT DNA, however it still produced an 
average S/B ratio of 5.3. This nonspecific signal is higher than expected but may be due, in part, to 
the contamination shown in the negative control. The WT sensor produced a lower signal when 
combined in the assay with the gyrA 94 XDR-TB DNA Multiplex PCR analytes. The lower signal 
was expected because the WT sensor is not specific for the gyrA MT. The S/B ratio of 4.04 may also 
be due to the contamination that is shown in the negative control. When assayed with the WT 
synthetic analyte (1 nM), the WT sensor produced a moderate S/B ratio of 4.7. Since the sensor was 
designed to be specific for the WT analyte, the S/B ratio was expected to be higher. The WT sensor 
produced little signal when combined with the MT synthetic analyte. The low S/B ratio of 2.2 was 
expected because the WT sensor is not specific for the MT analyte.  
The difference in the S/B ratio of the WT and Mt analytes indicates that the sensor can 
successfully differentiate between the pure analytes. However, the contamination of the negative “no 
DNA” is problematic and the high signal from the gyrA D94G BCG MT and gyrA D94G XDR-TB  
multiplex PCR analytes indicate that further optimization of the WT sensor is necessary to 




Figure 11: gyrA WT Sensor S/B Ratios 
Negative Control:  “no DNA” Multiplex PCR control. WT CDC: gyrA 94 Multiplex PCR analytes from WT CDC1551. 
gyrA D94G BCG: gyrA 94 Multiplex PCR analytes from gyrA D94G BCG MT DNA. gyrA D94G XDR-TB: gyrA D94G 
XDR-TB DNA Multiplex PCR analytes. WT syn (1 nM): WT synthetic analyte with a final concentration of 1 nM. MT 
syn (1 nM): MT synthetic analyte with a final concentration of 1 nM. 
 
Figure 12 shows the S/B ratios of the optimized A1-MT gyrA sensor. The negative multiplex 
PCR analyte, produced a low S/B ratio of 1.36. This was expected because no signal should have 
been seen from the “no DNA” control. The MT sensor also produced a low signal when assayed 
with the gyrA 94 Multiplex PCR analytes amplified from WT CDC1551. The S/B ratio of 1.54 was 
expected because the sensor is not specific for the WT template. When assayed with the multiplex 
PCR analytes amplified from the gyrA D94G BCG MT DNA, the MT sensor produced a S/B ratio 
of 7.42. This high signal was expected as the MT sensor was designed to be specific for the SNP. 
The MT sensor also produced a high signal when assayed with the gyrA D94G XDR-TB DNA 
Multiplex PCR analytes. The S/B ratio of 7.43 was expected because the gyrA D94G XDR-TB 
DNA also contains the SNP that the MT sensor is specific for. 
When assayed with the WT synthetic analyte (1 nM), the MT sensor produced a S/B ratio of 
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sensor produced a high signal when combined with the MT synthetic analyte. The high S/B ratio of 
5.35 was expected because the MT sensor was designed to be specific for the MT analyte. The high 
S/B ratios of the WT (both CDC1551 and synthetic) multiplex’s and the low S/B ratios of the MT 
(5.1, 1598, and synthetic) MT multiplex analytes indicate that the sensor can successfully distinguish 
the SNP.  
 
 
Figure 12: gyrA MT Sensor S/B Ratios 
Negative Control:  “no DNA” Multiplex PCR control. WT CDC: gyrA 94 Multiplex PCR analytes from WT CDC1551. 
gyrA D94G BCG: gyrA 94 Multiplex PCR analytes from gyrA D94G BCG MT DNA. gyrA D94G XDR-TB: gyrA D94G 
XDR-TB DNA Multiplex PCR analytes. WT syn (1 nM): WT synthetic analyte with a final concentration of 1 nM. MT 
syn (1 nM): MT synthetic analyte with a final concentration of 1 nM. 
Figure 13 shows the S/B ratios of the species specific 23S rRNA sensor. The negative 
control, which was expected to have a low S/B ratio below 2, was slightly higher than expected due 
to contamination of the multiplex “no DNA” control.  The S/B ratios of the species specific 23s 
rRNA are expected to be similar and high amongst the WT gyrA 94 CDC1551, gyrA D94G BCG 
MT, and gyrA D94G XDR-TB Multiplex PCR products, and Mtb synthetic (1 nM) analytes because 































results with the S/B ratios of 4.25, 4.89, 3.82, and 6.06. The slight variability that is present may be 
due to differences in PCR amplification. The slightly higher Mtb synthetic analyte S/B ratio of 6.06 
is because the sensors were designed specifically for that analyte therefore should produce the 
highest signal. M. absessus (Mabs) and M. smegmatis (Msmeg) are not members of Mtb and lack the 
species identifying 23S rRNA, therefore they were expected to yield a low S/B ratio. When assayed 
with the Mabs and Msmege synthetic analyte (1 nM), the WT sensor produced very low S/B ratios of 
1.15 and 1.02, respectively.  
The difference in the S/B ratio of Mtb versus Non-Mtb (NTM) indicates that the sensor can 
successfully differentiate between the species. However, the contamination of the negative “no 
DNA” is problematic and further optimization is necessary to yield a more accurate control.  
 
Figure 13: 23S rRNA Sensor S/B Ratios 
Mtb syn (1 nM): Mtb synthetic analyte with a final concentration of 1 nM. Mab syn (1 nM): Mabs synthetic analyte with a 






































Due to the rise of MDR-TB and XDR-TB worldwide, the need for new diagnostic assays 
that are able to efficiently detect Mtb while synonymously identifying drug resistance has increased. 
One-third of the world’s population is currently living with TB and about 9 million more people 
became infected annually. The TB infection causes over 1.3 million deaths each year. TB’s ability to 
be transmitted through breathing in the aerosolized droplets coughed up by someone with active 
disease has given it the potential to unknowingly spread to others at a disastrous rate. In order to try 
to address this problem, this project was aimed to develop a novel diagnostic technique combines 
DNAzyme sensor assays with multiplex PCR analytes to enable the rapid, POC detection of 
tuberculosis and identification of multi-drug resistance. 
The aims of this project were to construct a BCG strain with gyrA D94G drug resistant 
SNPs, develop a multiplex PCR that amplifies chromosomal regions necessary for TB detection and 
DST, and design SNP specific binary sensors to enable the identification of any drug resistant Mtb 
mutations present. PCR amplification and TOPO cloning allowed the amplification and insertion of 
the WT gyrA gene, before it was able to be mutated to contain the SNP of interest using a 
QuikChange mutagenesis method. Then the gyrA gene containing the resistance-conferring SNP was 
transformed into the M. bovis BCG vaccine strain using electroporation. Construction of a validated 
panel of BCG with the gyrA D94G drug resistant SNP allowed us to have safe template strains to 
test the Multiplex assay. A 12 primer multiplex PCR that amplifies 6 chromosomal regions necessary 
for TB detection and DST was designed. After multiple trials, a 30 minute PCR reaction with 50 
cycles provided the most efficient amplification. While contamination of the negative “no DNA” 
proved to be problematic, the multiplex was successfully optimized for the amplification of 6 targets 
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in a single reaction for use in the DNAzyme Assay.  The development of gyrA D94G SNP specific 
binary sensors that are able to identify the drug resistant Mtb were designed for use in the DNAzyme 
assay. The sensors were optimized for specificity and high signal to background ratios and then the 
LOD and their ability to detect multiplex PCR analytes were tested in multiple assays. While the MT 
sensors proved to be specific while still maintaining a high signal, the WT sensors require further 
optimization  
Future work for this project includes the development of BCG strains containing other 
drugR conferring SNPs. This will enable us to safely optimize the DNAzyme diagnostic assay. 
Further testing of SNP specific sensors that will be able to discriminate between the SNPs and still 
produce a high signal. Other work includes the development of a multi-color assay with specific 
colors detecting specific resistances in a single tube. This way we might be able to give a molecular 
profile of the specific drugR present.  
The final outcome of this project has led to the development of a novel method for 
detecting TB and identifying the drugR present. With the emergence of MDR-TB, this project has 
furthered the development of future drugR diagnostic assays that will enable the prompt and specific 
diagnosis of TB allowing for the implementation of an effective treatment regimen that will 
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